Parse Biosciences , a leader in providing affordable and scalable single-cell sequencing solutions, announced the acquisition of data analysis software company Biomage . With the acquisition, customers will have access to a more comprehensive suite of single-cell data analysis tools through an intuitive interface. By combining Biomage’s powerful data analysis tools with Parse’s Evercode combinatorial barcoding technology, researchers have access to deeper insights with significantly faster analysis time.
Biomage hosts and supports the largest community instance of Cellenics ® , a cloud-based single-cell RNA sequencing data analysis platform. With an intuitive interface, the Cellenics platform offers researchers powerful analysis tools without the need for bioinformatics experience. Since launching the platform in 2021, Biomage has reduced average analysis times from six months to two weeks. The platform has a user base of almost 4,000 researchers worldwide, with approximately 200 scientists accessing the platform daily.
“The platform has quickly become a trusted resource for single-cell researchers around the world,” said Charles Roco, co-founder and CTO of Parse Biosciences. “Integrating the software into Parse’s portfolio of offerings will enable our customers to richly and dynamically explore single-cell data in a shorter time than anything currently available.”
“Combining Parse’s scalability, which makes it possible to perform exponentially more experiments than other single cell technologies, with Biomage’s technology to accelerate analysis is an unbeatable combination that will have considerable positive implications for the single cell community,” noted Adam Kurkiewicz, co-founder and CEO of Biomage.
All current Biomage team members will be integrated into the existing Parse team.
Parse Biosciences is a global life sciences company whose mission is to accelerate development in the areas of human health and scientific research. Empowering researchers to perform single-cell sequencing with unprecedented scale and ease, their pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
Founded on a transformative technology invented at the University of Washington, Parse has raised more than $100 million and is used by more than 1,000 labs around the world. Its growing product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis software tool.
Parse Biosciences is headquartered in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot space and state-of-the-art laboratory.
The original language text of this announcement is the official authorized version. Translations are provided as a facility only and must refer to the text in the original language, which is the only version of the text that has legal effect.
SOURCE: Businesswire